276 related articles for article (PubMed ID: 28523352)
1. Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer.
Henderson S; Purdie C; Michie C; Evans A; Lerski R; Johnston M; Vinnicombe S; Thompson AM
Eur Radiol; 2017 Nov; 27(11):4602-4611. PubMed ID: 28523352
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
[TBL] [Abstract][Full Text] [Related]
3. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
4. [Texture analysis based on contrast-enhanced MRI can predict treatment response to neoadjuvant chemotherapy of breast cancer].
Sun SH; Zhou CW; Zhao LY; Zhang RZ; Ouyang H
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):344-349. PubMed ID: 28535650
[No Abstract] [Full Text] [Related]
5. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
[TBL] [Abstract][Full Text] [Related]
6. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
Mitchell D; Hruska CB; Boughey JC; Wahner-Roedler DL; Jones KN; Tortorelli C; Conners AL; O'Connor MK
Clin Nucl Med; 2013 Dec; 38(12):949-56. PubMed ID: 24152645
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy for Primary Breast Cancer Comparing Interim Ultrasound, Shear Wave Elastography and MRI.
Evans A; Whelehan P; Thompson A; Purdie C; Jordan L; Macaskill J; Waugh S; Fuller-Pace F; Brauer K; Vinnicombe S
Ultraschall Med; 2018 Aug; 39(4):422-431. PubMed ID: 28934812
[TBL] [Abstract][Full Text] [Related]
10. Time Course Changes of Synthetic Relaxation Time During Neoadjuvant Chemotherapy in Breast Cancer: The Optimal Parameter for Treatment Response Evaluation.
Zhao R; Du S; Gao S; Shi J; Zhang L
J Magn Reson Imaging; 2023 Oct; 58(4):1290-1302. PubMed ID: 36621982
[TBL] [Abstract][Full Text] [Related]
11. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
Wu J; Gong G; Cui Y; Li R
J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.
Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
AJR Am J Roentgenol; 2019 Oct; 213(4):944-952. PubMed ID: 31237439
[No Abstract] [Full Text] [Related]
13. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
Parikh J; Selmi M; Charles-Edwards G; Glendenning J; Ganeshan B; Verma H; Mansi J; Harries M; Tutt A; Goh V
Radiology; 2014 Jul; 272(1):100-12. PubMed ID: 24654970
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Teruel JR; Heldahl MG; Goa PE; Pickles M; Lundgren S; Bathen TF; Gibbs P
NMR Biomed; 2014 Aug; 27(8):887-96. PubMed ID: 24840393
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
[TBL] [Abstract][Full Text] [Related]
17. Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer.
Al-Hattali S; Vinnicombe SJ; Gowdh NM; Evans A; Armstrong S; Adamson D; Purdie CA; Macaskill EJ
Cancer Imaging; 2019 Dec; 19(1):91. PubMed ID: 31878958
[TBL] [Abstract][Full Text] [Related]
18. Deep Learning-Based Segmentation of Locally Advanced Breast Cancer on MRI in Relation to Residual Cancer Burden: A Multi-Institutional Cohort Study.
Janse MHA; Janssen LM; van der Velden BHM; Moman MR; Wolters-van der Ben EJM; Kock MCJM; Viergever MA; van Diest PJ; Gilhuijs KGA
J Magn Reson Imaging; 2023 Dec; 58(6):1739-1749. PubMed ID: 36928988
[TBL] [Abstract][Full Text] [Related]
19. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
[TBL] [Abstract][Full Text] [Related]
20. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
Kim SY; Cho N; Shin SU; Lee HB; Han W; Park IA; Kwon BR; Kim SY; Lee SH; Chang JM; Moon WK
Eur Radiol; 2018 Jul; 28(7):2986-2995. PubMed ID: 29380033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
